10-K: Liquidia Reports Initial YUTREPIA Sales Amidst Legal Battles

Liquidia Corporation achieved its first product sales of YUTREPIA in 2025, generating $148.3 million, but faces significant ongoing litigation and continued net losses.

Summary

• Liquidia Corporation reported total revenue of $158.3 million for the year ended December 31, 2025, a substantial increase from $14.0 million in 2024, driven by the commercial launch of YUTREPIA.
• Net product sales from YUTREPIA (treprostinil) inhalation powder, approved by the FDA in May 2025 for PAH and PH-ILD, reached $148.3 million since its commercialization began in June 2025.
• Service revenue, primarily from the promotion agreement with Sandoz for generic treprostinil injection, decreased to $10.0 million in 2025 from $14.0 million in 2024, mainly due to lower sales volumes.
• The company incurred a net loss of $68.9 million for the year ended December 31, 2025, an improvement from a $128.3 million net loss in 2024, but still reflecting significant operating expenses.
• Selling, general, and administrative expenses surged by 93% to $157.2 million in 2025, up from $81.6 million in 2024, primarily due to increased personnel, commercial, consulting, and legal fees associated with YUTREPIA's commercialization and ongoing litigation.
• Research and development expenses decreased by 18% to $39.3 million in 2025, from $47.8 million in 2024, reflecting a shift towards commercialization activities for YUTREPIA, partially offset by increased clinical expenses for the L606 program.
• Liquidia had cash and cash equivalents of $190.7 million and an accumulated deficit of $626.3 million as of December 31, 2025.
• The company is actively developing L606, an investigational liposomal treprostinil formulation, with an open-label study ongoing and a worldwide placebo-controlled pivotal study initiated for PH-ILD.
• Multiple lawsuits with United Therapeutics are ongoing, including patent infringement claims (327 Patent, 782 Patent) seeking injunctive relief to remove YUTREPIA from the market, and trade secret misappropriation claims.
• Amendments to Restricted Stock Units and Stock Option Agreements were made on December 18, 2025, to provide full vesting of outstanding units and options upon the grantee's death.
• The company entered into a new exclusive licensing agreement with Vectura Limited in October 2025 for L606, involving an upfront payment of $2.0 million and potential milestones up to $104.5 million.
• A new 70,131 square foot manufacturing and office facility lease was signed in June 2025, with commencement expected in late 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period. While YUTREPIA's commercial launch and initial sales are positive, the substantial net losses and severe ongoing litigation risks, including potential market withdrawal, create significant uncertainty and financial pressure.

Positives

• YUTREPIA received full FDA approval in May 2025 for the treatment of both PAH and PH-ILD, marking a significant regulatory milestone.
• Commercialization of YUTREPIA commenced in June 2025, generating $148.3 million in net product sales in its first partial year.
• The company's net loss decreased by 46% from $128.3 million in 2024 to $68.9 million in 2025, indicating improved financial performance as YUTREPIA sales began.
• Operating cash flows turned positive in the fourth quarter of 2025, demonstrating early commercial traction.
• A global placebo-controlled pivotal study for L606, an investigational liposomal treprostinil, has been initiated for the treatment of PH-ILD, advancing the pipeline.
• The denial of United Therapeutics' motion for a preliminary injunction in the 782 Patent Litigation in May 2025 allowed YUTREPIA's commercialization to proceed without immediate interruption.
• Amendments to stock option and restricted stock unit agreements ensure full vesting upon grantee's death, enhancing employee benefits.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $626.3 million as of December 31, 2025.
• Service revenue from the Sandoz promotion agreement for generic treprostinil injection decreased by 28% to $10.0 million in 2025, primarily due to lower sales volumes.
• Selling, general and administrative expenses increased by 93% to $157.2 million in 2025, largely due to commercialization costs and legal fees.
• The availability of CADD-MS 3 infusion pumps for subcutaneous Treprostinil Injection is limited, and ICU Medical no longer manufactures or supports them, potentially constraining future sales of the generic product.
• The company relies on single suppliers for critical components of YUTREPIA (API, DPI device, encapsulation/packaging) and L606 (API, device), posing supply chain risks.
• Ongoing litigation with United Therapeutics, including patent infringement and trade secret misappropriation claims, could result in YUTREPIA's market withdrawal or substantial monetary damages.

Risks

• Dependence on the success of YUTREPIA and L606, which may fail to receive or maintain final marketing approval or be commercialized successfully.
• Multiple lawsuits initiated by United Therapeutics claiming patent infringement and trade secret misappropriation, potentially leading to YUTREPIA's market withdrawal or substantial damage claims.
• Inability to manufacture sufficient quantities of products to meet future commercial demand due to complex processes and reliance on third-party CMOs and single suppliers.
• Significant competition from large pharmaceutical companies with greater resources, potentially leading to superior product profiles or faster market entry for competitors.
• Expectation of significant expenses for the foreseeable future for commercialization and clinical trials, with future viability dependent on YUTREPIA revenue and additional external financing.
• Preclinical studies and clinical trials may not be successful, or delays may occur, increasing costs and impairing commercialization ability.
• Dependence on Sandoz for the manufacture, supply, and FDA compliance of Treprostinil Injection, over which Liquidia has limited control.
• Reliance on third-party medical devices (dry powder inhalers, nebulizers, infusion pumps) for product administration, which Liquidia does not control and may face supply or regulatory clearance issues.
• Market acceptance of YUTREPIA and Treprostinil Injection is uncertain and depends on factors like efficacy, safety, convenience, pricing, reimbursement, and competition.
• L606 is based on novel liposomal technology, making development time and cost, and regulatory approval, difficult to predict.
• Operations are concentrated in Morrisville, North Carolina, making them vulnerable to natural or man-made disasters and other unforeseen events.
• Inability to scale or maintain commercial operations, including marketing and sales capabilities, or secure effective third-party collaborations.
• Volatility in the market price of common stock due to various factors, including clinical trial results, litigation outcomes, and competitive landscape.
• Potential limitations on the use of net operating loss carryforwards and research and development tax credits due to ownership changes (Section 382).
• Exposure to claims and inability to obtain or maintain adequate product liability insurance.
• Adverse effects of public health emergencies, global economic uncertainty, and geopolitical instability on business operations and financial performance.
• Disruptions at government agencies (FDA, SEC) due to funding shortages, shutdowns, or personnel issues, potentially delaying regulatory approvals.
• Failure to adapt to or comply with evolving regulatory requirements or investor/stakeholder expectations and standards, including ESG matters.
• Risks associated with adopting or incorporating artificial intelligence (AI) technology, including defects, security breaches, and evolving regulatory frameworks.
• Potential for an impairment of long-lived contract acquisition costs and intangible assets, including goodwill, due to changes in business success or regulatory approvals.

Future Outlook

The company plans to conduct additional studies for YUTREPIA in pediatric patients and for new indications such as PH-COPD, IPF, PPF, and SSc-RP. A global placebo-controlled pivotal study for L606 in PH-ILD has been initiated, with plans to pursue additional indications for L606 that align with YUTREPIA's studied diseases. Efforts are underway to identify and develop a new subcutaneous pump option for Treprostinil Injection to address current supply constraints.

Management Comments

• Management believes YUTREPIA can become the prostacyclin of first choice across the disease continuum in PAH and PH-ILD due to its convenience, low-effort device, and ability to titrate to higher doses.
• Management acknowledges the uncertainty of generating sustained revenue from YUTREPIA sales and the need for additional capital if current revenues are insufficient to fund future operations and meet debt covenants.
• Management is committed to vigorously defending against ongoing litigation, including claims that could impact YUTREPIA's market presence.

Industry Context

StockSavvy.ai notes that Liquidia operates in a highly competitive biopharmaceutical market, particularly in pulmonary hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The market for inhaled treprostinil therapies is intensifying with competitors like United Therapeutics (Tyvaso, Tyvaso DPI, Remodulin, Ralinepag, Treprostinil SMI) and Insmed (TPIP) actively developing and commercializing products. Liquidia's YUTREPIA, an inhaled dry powder treprostinil, competes directly with United Therapeutics' Tyvaso DPI. The company's L606, a liposomal treprostinil, aims to offer improved dosing frequency and tolerability. The generic treprostinil injection market, where Liquidia partners with Sandoz, is also experiencing increased competition and supply chain challenges with medical devices. The broader industry trend shows continued development of new mechanisms of action and combination therapies, alongside increasing governmental scrutiny on drug pricing and reimbursement.

Comparison to Industry Standards

• YUTREPIA's ability to achieve higher dose levels (up to 291.5 mcg QID in PAH, 424 mcg QID in PH-ILD) compared to the labeled doses of other inhaled treprostinil therapies like Tyvaso (9-12 nebulized breaths per session, comparable to 54-64 mcg) positions it as a potentially more effective option for patients requiring increased drug exposure.
• YUTREPIA's low-effort dry-powder inhaler (RS00 Model DPI) offers a convenience advantage over nebulized therapies like United Therapeutics' Tyvaso and Johnson & Johnson's Ventavis, which require more frequent and burdensome administration.
• L606, with its investigational twice-daily liposomal formulation and short-duration next-generation nebulizer, aims to provide best-in-class treprostinil exposure over 24 hours, potentially offering improved tolerability and efficacy compared to existing inhaled products.
• In the generic parenteral treprostinil market, Liquidia's partnership with Sandoz faces increasing competition from other generic manufacturers like Teva, Par Pharmaceutical, Dr. Reddys, and Alembic, which could lead to significant price declines, similar to broader generic drug market trends.
• The discontinuation of support for the CADD-MS 3 infusion pump by ICU Medical for subcutaneous Treprostinil Injection creates a disadvantage compared to United Therapeutics' Remunity pump for Remodulin, which offers prefilled cassettes and water-resistant casing, enhancing patient convenience.

Corporate Governance

Legal Proceedings

• **327 Patent Litigation (U.S. District Court for the District of Delaware, Case No. 1:23-cv-00975-RGA):** United Therapeutics alleges infringement of U.S. Patent No. 11,826,327 ('327 Patent) by YUTREPIA, specifically related to the PH-ILD indication. United Therapeutics is seeking injunctive relief to remove YUTREPIA from the market and monetary damages. Trial was held in June 2025, and the court's decision is pending. An adverse decision could lead to withdrawal of FDA approval for YUTREPIA or removal of the PH-ILD indication from its label, materially disrupting business.
• **782 Patent Litigation (U.S. District Court for the Middle District of North Carolina, Case No. 1:25CV368):** United Therapeutics alleges infringement of U.S. Patent No. 11,357,782 ('782 Patent) by YUTREPIA. United Therapeutics sought a preliminary injunction to prevent manufacturing, marketing, and selling YUTREPIA, which was denied in May 2025. United Therapeutics is seeking injunctive relief and monetary damages. Briefing on a motion to consolidate and stay is ongoing.
• **Trade Secret Litigation (Superior Court in Durham County, North Carolina):** United Therapeutics alleges Liquidia and a former employee conspired to misappropriate trade secrets and engaged in unfair trade practices. Motions for summary judgment by both Liquidia and the former employee were denied. United Therapeutics is seeking injunctive relief (potential YUTREPIA market removal) and monetary damages. A trial date has not yet been set.
• **Breach of Contract Litigation (Superior Court in Durham County, North Carolina):** United Therapeutics alleges a former employee breached employment agreements by failing to assign patent interests to United Therapeutics, claiming reliance on United Therapeutics' confidential information for YUTREPIA's development. United Therapeutics seeks declaratory judgment for assignment of intellectual property rights to them. Liquidia's motion to dismiss was denied in May 2025. If United Therapeutics prevails, Liquidia could be required to assign an interest in certain intellectual property, including the '494 patent.
• **494 Patent Litigation (U.S. District Court for the Middle District of North Carolina, Case No. 1:25-cv-00299):** Liquidia filed a complaint against United Therapeutics for infringement of U.S. Patent No. 10,898,494 ('494 Patent) with respect to its Tyvaso DPI product. United Therapeutics' motion to dismiss was denied, but its motion to stay the lawsuit was granted in November 2025, pausing the proceedings.

Related Party Transactions

• PBM RG Holdings, LLC, controlled by Paul B. Manning (a member of Liquidia's Board of Directors and a major stockholder), is party to a Litigation Funding and Indemnification Agreement with Liquidia PAH. PBM controls the RareGen Litigation and reimburses Liquidia PAH for litigation expenses not covered by Henderson SPV, LLC, and receives any net proceeds from the litigation after Henderson's entitlement.
• A fund affiliated with Paul B. Manning participated in Liquidia's September 2024 public offering, purchasing approximately $3.0 million in common stock on the same terms as other purchasers.
• Caligan Partners LP, Liquidia's largest stockholder, participated in a private placement concurrently with the September 2024 public offering, purchasing $10.0 million in common stock.

Stakeholder Impact

• **Shareholders:** Face significant risk due to ongoing litigation that could materially impact YUTREPIA's commercialization and the company's financial performance. Potential for stock price volatility is high. Dilution risk from future capital raises.
• **Employees:** Benefit from enhanced equity vesting terms (full vesting upon death). However, the company's financial stability and growth prospects are tied to product success and litigation outcomes, which could affect job security and future compensation.
• **Customers (Patients & Healthcare Providers):** Benefit from the availability of YUTREPIA as a new treatment option for PAH and PH-ILD, offering convenience and higher dosing potential. However, potential market withdrawal due to litigation or supply chain issues for Treprostinil Injection could disrupt patient access to therapies.
• **Suppliers:** Face risks related to Liquidia's dependence on single-source suppliers for key components, where disruptions could impact their business. Conversely, Liquidia's growth could mean increased demand for their services.
• **Creditors (HCR):** The HCR Agreement contains covenants and fixed quarterly payments. Failure to meet financial obligations or a material adverse event could accelerate debt repayment, potentially leading to HCR foreclosing on collateral, including intellectual property.

Next Steps

• Continue to pursue additional studies for YUTREPIA, including in pediatric patients and for new indications such as PH-COPD, IPF, PPF, and SSc-RP.
• Advance the L606 program, including the ongoing open-label study and the initiated worldwide placebo-controlled pivotal study for PH-ILD.
• Support efforts to identify and develop a new subcutaneous pump option for infusion of Treprostinil Injection to maintain its availability.
• Build out the new 70,131 square foot manufacturing and office facility in Morrisville, North Carolina, with commencement expected in late 2026.
• Monitor and respond to ongoing litigation with United Therapeutics, including the pending decision in the 327 Patent Litigation and briefing in the 782 Patent Litigation.

Key Dates

Recommendation

The company has achieved a significant milestone with YUTREPIA's FDA approval and initial commercial sales, demonstrating market entry and generating substantial initial revenue. However, the substantial ongoing litigation with United Therapeutics, which includes demands for YUTREPIA's market withdrawal and significant damages, introduces extreme uncertainty and could severely impact future revenue and profitability. While the pipeline (L606) shows promise, the immediate legal risks warrant a cautious 'hold' stance, as the outcome of these proceedings will be a primary determinant of the company's near-term value. Investors should closely monitor legal developments.

Keywords

YUTREPIA, treprostinil, PAH, PH-ILD, pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, L606, PRINT technology, biopharmaceutical, SEC filing, 10-K, FDA approval, commercialization, clinical trials, litigation, intellectual property, drug development, rare diseases, orphan drug, Sandoz, United Therapeutics, Vectura, Pharmosa, dry powder inhaler, nebulizer, financial results, net loss, revenue, biotechnology